Commitment
Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic identifies the patients with the corresponding molecular signature who are the best candidates for therapy.
News & Events
Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA
Targeted Tozaride Drug Therapy is effective for Small Cell Lung Cancer SOMERVILLE, Mass.— July 24, 2017 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017.…
Read MoreAndarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market
Tozaride has demonstrated clinical effectiveness in treating lung cancer SOMERVILLE, Mass.— September 6, 2017— Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights…
Read MoreAndarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting
Targeted Tozaride Drug Therapy for Small Cell Lung and neuroendocrine Cancer SOMERVILLE, Mass.— June 2, 2017 — Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO)…
Read More